{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:08:55Z","timestamp":1780499335523,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:00:00Z","timestamp":1585958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41390-020-0870-1","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:03:09Z","timestamp":1585958589000},"page":"118-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Steroid hormone analysis of adolescents and young women with polycystic ovarian syndrome and adrenocortical dysfunction using UPC2-MS\/MS"],"prefix":"10.1038","volume":"89","author":[{"given":"Amanda C.","family":"Swart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therina","family":"du Toit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Gourgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Keil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio R.","family":"Faucz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Stratakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,4]]},"reference":[{"key":"870_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield, R. L. & Ehrmann, D. A. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev. 37, 467\u2013520 (2016).","journal-title":"Endocr. Rev."},{"key":"870_CR2","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1210\/jc.2015-4019","volume":"101","author":"E Gourgari","year":"2016","unstructured":"Gourgari, E. et al. Bilateral adrenal hyperplasia as a possible mechanism for hyperandrogenism in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 101, 3353\u20133360 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s13361-012-0524-6","volume":"24","author":"CA Crutchfield","year":"2013","unstructured":"Crutchfield, C. A. et al. Comprehensive analysis of LC\/MS data using pseudocolor plots. J. Am. Soc. Mass Spectrom. 24, 230\u2013237 (2013).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"870_CR4","first-page":"946","volume":"84","author":"R Azziz","year":"1999","unstructured":"Azziz, R., Black, V. Y., Knochenhauer, E. S., Hines, G. A. & Boots, L. R. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J. Clin. Endocrinol. Metab. 84, 946\u2013950 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1210\/jc.2012-2912","volume":"98","author":"J Rege","year":"2013","unstructured":"Rege, J. et al. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J. Clin. Endocrinol. Metab. 98, 1182\u20131188 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR6","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.fertnstert.2016.06.039","volume":"106","author":"KH Maas","year":"2016","unstructured":"Maas, K. H. et al. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome. Fertil. Steril. 106, 1252\u20131257 (2016).","journal-title":"Fertil. Steril."},{"key":"870_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11154-007-9054-0","volume":"8","author":"BO Yildiz","year":"2007","unstructured":"Yildiz, B. O. & Azziz, R. The adrenal and polycystic ovary syndrome. Rev. Endocr. Metab. Disord. 8, 331\u2013342 (2007).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"870_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jsbmb.2017.12.016","volume":"178","author":"C Kamrath","year":"2018","unstructured":"Kamrath, C., Wettstaedt, L., Boettcher, C., Hartmann, M. F. & Wudy, S. A. Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia. J. Steroid Biochem. Mol. Biol. 178, 221\u2013228 (2018).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"870_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1210\/jc.2016-3285","volume":"102","author":"MW O\u2019Reilly","year":"2017","unstructured":"O\u2019Reilly, M. W. et al. 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 102, 840\u2013848 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR10","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1210\/js.2018-00412","volume":"3","author":"SR Davis","year":"2019","unstructured":"Davis, S. R., Turcu, A. F., Robinson, P. J. & Bell, R. J. Exogenous testosterone does not influence 11-oxygenated C19 steroid concentrations in healthy postmenopausal women. J. Endocr. Soc. 3, 670\u2013677 (2019).","journal-title":"J. Endocr. Soc."},{"key":"870_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MED.0000000000000334","volume":"24","author":"AF Turcu","year":"2017","unstructured":"Turcu, A. F. & Auchus, R. J. Clinical significance of 11-oxygenated androgens. Curr. Opin. Endocrinol. Diabetes Obes. 24, 252\u2013259 (2017).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"870_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jsbmb.2016.06.009","volume":"166","author":"T du Toit","year":"2017","unstructured":"du Toit, T. et al. Profiling adrenal 11beta-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC(2)-MS\/MS quantification of 11beta-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J. Steroid Biochem. Mol. Biol. 166, 54\u201367 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"870_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.mce.2017.09.026","volume":"461","author":"T du Toit","year":"2018","unstructured":"du Toit, T. & Swart, A. C. Inefficient UGT-conjugation of adrenal 11beta-hydroxyandrostenedione metabolites highlights C11-oxy C19 steroids as the predominant androgens in prostate cancer. Mol. Cell. Endocrinol. 461, 265\u2013276 (2018).","journal-title":"Mol. Cell. Endocrinol."},{"key":"870_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1530\/EJE-15-1181","volume":"174","author":"AF Turcu","year":"2016","unstructured":"Turcu, A. F. et al. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur. J. Endocrinol. 174, 601\u2013609 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"870_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jchromb.2018.02.023","volume":"1080","author":"T du Toit","year":"2018","unstructured":"du Toit, T., Stander, M. A. & Swart, A. C. A high-throughput UPC(2)-MS\/MS method for the separation and quantification of C19 and C21 steroids and their C11-oxy steroid metabolites in the classical, alternative, backdoor and 11OHA4 steroid pathways. J. Chromatogr. B 1080, 71\u201381 (2018).","journal-title":"J. Chromatogr. B"},{"key":"870_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsbmb.2015.04.009","volume":"153","author":"LM Bloem","year":"2015","unstructured":"Bloem, L. M. et al. Advances in the analytical methodologies: profiling steroids in familiar pathways\u2014challenging dogmas. J. Steroid Biochem. Mol. Biol. 153, 80\u201392 (2015).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"870_CR17","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1124\/dmd.104.003327","volume":"33","author":"MH Choi","year":"2005","unstructured":"Choi, M. H., Skipper, P. L., Wishnok, J. S. & Tannenbaum, S. R. Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab. Dispos. 33, 714\u2013718 (2005).","journal-title":"Drug Metab. Dispos."},{"key":"870_CR18","first-page":"98","volume":"77","author":"P Swart","year":"1993","unstructured":"Swart, P., Swart, A. C., Waterman, M. R., Estabrook, R. W. & Mason, J. I. Progesterone 16 alpha-hydroxylase activity is catalyzed by human cytochrome P450 17 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 77, 98\u2013102 (1993).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR19","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1046\/j.1432-1033.2002.03268.x","volume":"269","author":"AC Swart","year":"2002","unstructured":"Swart, A. C., Kolar, N. W., Lombard, N., Mason, J. I. & Swart, P. Baboon cytochrome P450 17alpha-hydroxylase\/17,20-lyase (CYP17). Eur. J. Biochem. 269, 5608\u20135616 (2002).","journal-title":"Eur. J. Biochem."},{"key":"870_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mce.2016.09.025","volume":"441","author":"D van Rooyen","year":"2017","unstructured":"van Rooyen, D. et al. The metabolic fate and receptor interaction of 16alpha-hydroxyprogesterone and its 5alpha-reduced metabolite, 16alpha-hydroxy-dihydroprogesterone. Mol. Cell Endocrinol. 441, 86\u201398 (2017).","journal-title":"Mol. Cell Endocrinol."},{"key":"870_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jsbmb.2017.12.014","volume":"178","author":"D van Rooyen","year":"2018","unstructured":"van Rooyen, D., Gent, R., Barnard, L. & Swart, A. C. The in vitro metabolism of 11beta-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway. J. Steroid Biochem. Mol. Biol. 178, 203\u2013212 (2018).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"870_CR22","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2005-1890","volume":"91","author":"V Tonetto-Fernandes","year":"2006","unstructured":"Tonetto-Fernandes, V. et al. Serum 21-deoxycortisol, 17-hydroxyprogesterone, and 11-deoxycortisol in classic congenital adrenal hyperplasia: clinical and hormonal correlations and identification of patients with 11beta-hydroxylase deficiency among a large group with alleged 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 91, 2179\u20132184 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR23","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1210\/jc.2015-1023","volume":"100","author":"AF Turcu","year":"2015","unstructured":"Turcu, A. F. et al. Profiles of 21-carbon steroids in 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 100, 2283\u20132290 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1056\/NEJM199402173300703","volume":"330","author":"A Rodin","year":"1994","unstructured":"Rodin, A., Thakkar, H., Taylor, N. & Clayton, R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N. Engl. J. Med. 330, 460\u2013465 (1994).","journal-title":"N. Engl. J. Med."},{"key":"870_CR25","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1210\/jc.2009-0837","volume":"94","author":"DA Vassiliadi","year":"2009","unstructured":"Vassiliadi, D. A. et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 94, 3558\u20133566 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"870_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jsbmb.2017.07.034","volume":"174","author":"L Barnard","year":"2017","unstructured":"Barnard, L., Gent, R., van Rooyen, D. & Swart, A. C. Adrenal C11-oxy C21 steroids contribute to the C11-oxy C19 steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone. J. Steroid Biochem. Mol. Biol. 174, 86\u201395 (2017).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"870_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jsbmb.2019.02.013","volume":"189","author":"R Gent","year":"2019","unstructured":"Gent, R., du Toit, T., Bloem, L. M. & Swart, A. C. The 11beta-hydroxysteroid dehydrogenase isoforms: pivotal catalytic activities yield potent C11-oxy C19 steroids with 11betaHSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis. J. Steroid Biochem. Mol. Biol. 189, 116\u2013126 (2019).","journal-title":"J. Steroid Biochem. Mol. Biol."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0870-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0870-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:30:52Z","timestamp":1684618252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-0870-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-0870-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,4]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.S. holds patent on the <i>PRKAR1A<\/i>, <i>PDE11A<\/i>, and <i>GPR101<\/i> genes and\/or their function and his laboratory has received research funding from Pfizer Inc. F.R.F. holds patent on the <i>GPR101<\/i> gene and\/or its function. The other authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all HVs and adult patients; the patients\u2019 parents for all pediatric patients and older children signed an assent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}